Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy

Sadako Akashi-Tanaka, Mutsuko Omatsu, Chikako Shimizu, Masashi Ando, Kotoe Terada, Tadahiko Shien, Takayuki Kinoshita, Yasuhiro Fujiwara, Kunihiko Seki, Tadashi Hasegawa, Takashi Fukutomi

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Neoadjuvant endocrine therapy (NAET) can expand the number of breast cancer patients who can be treated with breast-conserving surgery and can predict benefit from adjuvant endocrine therapy. Because no validated surrogate markers for long-term outcome have been established, we conducted prospective trials to evaluate pathological response and Ki-67 index following treatment with tamoxifen or anastrozole. The study population included postmenopausal women with operable breast tumors that were both estrogen and progesterone receptor-positive and larger than 3 cm. Response was classified as pathological response (minimal response or better) and non-response. Non-responding (25.5%, vs. response 85.9%, p=0.002), axillary node-positive (58.4% vs. node negative 100%, p=0.045), and high pretreatment Ki-67 index (41.4% vs. low Ki-67 87.1%, p=0.03) patients were significantly associated with poor 5-year relapse-free survival. Multivariate analysis of relapse-free survival indicated that pathological response was independent. Therefore, pathological response may be a favorable prognostic factor after NAET.

Original languageEnglish
Pages (from-to)482-488
Number of pages7
JournalBreast
Volume16
Issue number5
DOIs
Publication statusPublished - Oct 2007
Externally publishedYes

Fingerprint

Neoadjuvant Therapy
Breast Neoplasms
Recurrence
Survival
Segmental Mastectomy
Progesterone Receptors
Tamoxifen
Estrogen Receptors
Multivariate Analysis
Biomarkers
Therapeutics
Population
anastrozole

Keywords

  • Breast cancer
  • Ki-67
  • Neoadjuvant endocrine therapy
  • Pathological response
  • Prognostic factor

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy. / Akashi-Tanaka, Sadako; Omatsu, Mutsuko; Shimizu, Chikako; Ando, Masashi; Terada, Kotoe; Shien, Tadahiko; Kinoshita, Takayuki; Fujiwara, Yasuhiro; Seki, Kunihiko; Hasegawa, Tadashi; Fukutomi, Takashi.

In: Breast, Vol. 16, No. 5, 10.2007, p. 482-488.

Research output: Contribution to journalArticle

Akashi-Tanaka, S, Omatsu, M, Shimizu, C, Ando, M, Terada, K, Shien, T, Kinoshita, T, Fujiwara, Y, Seki, K, Hasegawa, T & Fukutomi, T 2007, 'Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy', Breast, vol. 16, no. 5, pp. 482-488. https://doi.org/10.1016/j.breast.2007.02.003
Akashi-Tanaka, Sadako ; Omatsu, Mutsuko ; Shimizu, Chikako ; Ando, Masashi ; Terada, Kotoe ; Shien, Tadahiko ; Kinoshita, Takayuki ; Fujiwara, Yasuhiro ; Seki, Kunihiko ; Hasegawa, Tadashi ; Fukutomi, Takashi. / Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy. In: Breast. 2007 ; Vol. 16, No. 5. pp. 482-488.
@article{6719a819e37f43c19df4577e390fb02b,
title = "Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy",
abstract = "Neoadjuvant endocrine therapy (NAET) can expand the number of breast cancer patients who can be treated with breast-conserving surgery and can predict benefit from adjuvant endocrine therapy. Because no validated surrogate markers for long-term outcome have been established, we conducted prospective trials to evaluate pathological response and Ki-67 index following treatment with tamoxifen or anastrozole. The study population included postmenopausal women with operable breast tumors that were both estrogen and progesterone receptor-positive and larger than 3 cm. Response was classified as pathological response (minimal response or better) and non-response. Non-responding (25.5{\%}, vs. response 85.9{\%}, p=0.002), axillary node-positive (58.4{\%} vs. node negative 100{\%}, p=0.045), and high pretreatment Ki-67 index (41.4{\%} vs. low Ki-67 87.1{\%}, p=0.03) patients were significantly associated with poor 5-year relapse-free survival. Multivariate analysis of relapse-free survival indicated that pathological response was independent. Therefore, pathological response may be a favorable prognostic factor after NAET.",
keywords = "Breast cancer, Ki-67, Neoadjuvant endocrine therapy, Pathological response, Prognostic factor",
author = "Sadako Akashi-Tanaka and Mutsuko Omatsu and Chikako Shimizu and Masashi Ando and Kotoe Terada and Tadahiko Shien and Takayuki Kinoshita and Yasuhiro Fujiwara and Kunihiko Seki and Tadashi Hasegawa and Takashi Fukutomi",
year = "2007",
month = "10",
doi = "10.1016/j.breast.2007.02.003",
language = "English",
volume = "16",
pages = "482--488",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "5",

}

TY - JOUR

T1 - Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy

AU - Akashi-Tanaka, Sadako

AU - Omatsu, Mutsuko

AU - Shimizu, Chikako

AU - Ando, Masashi

AU - Terada, Kotoe

AU - Shien, Tadahiko

AU - Kinoshita, Takayuki

AU - Fujiwara, Yasuhiro

AU - Seki, Kunihiko

AU - Hasegawa, Tadashi

AU - Fukutomi, Takashi

PY - 2007/10

Y1 - 2007/10

N2 - Neoadjuvant endocrine therapy (NAET) can expand the number of breast cancer patients who can be treated with breast-conserving surgery and can predict benefit from adjuvant endocrine therapy. Because no validated surrogate markers for long-term outcome have been established, we conducted prospective trials to evaluate pathological response and Ki-67 index following treatment with tamoxifen or anastrozole. The study population included postmenopausal women with operable breast tumors that were both estrogen and progesterone receptor-positive and larger than 3 cm. Response was classified as pathological response (minimal response or better) and non-response. Non-responding (25.5%, vs. response 85.9%, p=0.002), axillary node-positive (58.4% vs. node negative 100%, p=0.045), and high pretreatment Ki-67 index (41.4% vs. low Ki-67 87.1%, p=0.03) patients were significantly associated with poor 5-year relapse-free survival. Multivariate analysis of relapse-free survival indicated that pathological response was independent. Therefore, pathological response may be a favorable prognostic factor after NAET.

AB - Neoadjuvant endocrine therapy (NAET) can expand the number of breast cancer patients who can be treated with breast-conserving surgery and can predict benefit from adjuvant endocrine therapy. Because no validated surrogate markers for long-term outcome have been established, we conducted prospective trials to evaluate pathological response and Ki-67 index following treatment with tamoxifen or anastrozole. The study population included postmenopausal women with operable breast tumors that were both estrogen and progesterone receptor-positive and larger than 3 cm. Response was classified as pathological response (minimal response or better) and non-response. Non-responding (25.5%, vs. response 85.9%, p=0.002), axillary node-positive (58.4% vs. node negative 100%, p=0.045), and high pretreatment Ki-67 index (41.4% vs. low Ki-67 87.1%, p=0.03) patients were significantly associated with poor 5-year relapse-free survival. Multivariate analysis of relapse-free survival indicated that pathological response was independent. Therefore, pathological response may be a favorable prognostic factor after NAET.

KW - Breast cancer

KW - Ki-67

KW - Neoadjuvant endocrine therapy

KW - Pathological response

KW - Prognostic factor

UR - http://www.scopus.com/inward/record.url?scp=34848917561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848917561&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2007.02.003

DO - 10.1016/j.breast.2007.02.003

M3 - Article

VL - 16

SP - 482

EP - 488

JO - Breast

JF - Breast

SN - 0960-9776

IS - 5

ER -